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Abstract 
Aneuploidy is a consistent genetic alteration of the cancer genome. At early steps in 
the sequence of malignant transformation during human tumorigenesis, 
chromosomal aneuploidies can be the first detectable genetic aberrations found. 
Since late diagnosis results in a significant reduction of average survival times, it is 
of high interest to elucidate proteins and pathways of genomic instability or 
stability. This may also give new insights into tumorigenesis and reveal clinically 
relevant targets for improved diagnostics and therapeutics. 
The high variability of protein expression complicates the clinical application of 
‘proteomics’, but continuous improvements in instrumentation, analytical 
methodologies, and labeling chemistries nowadays allow the thorough study and 
detection of tissue protein biomarkers. In addition, the need of strict quality 
controls of samples and clinical validation in large patient cohorts is important to 
transfer novel biomarkers into clinical use. In this manner, we detected genomic 
instability-specific protein alterations in colorectal and endometrial malignancies 
as detailed in this thesis.  
A comprehensive proteomic analysis of diploid and aneuploid colorectal cell lines 
and clinical tissues was carried out. We found that two proteins, TXNL1 and 
HDAC2, were not only significantly expressed in our 2-DE analysis and validated 
by Western blotting, but showed expression differences also in clinical samples 
discerning aneuploid from diploid carcinomas. We then analyzed protein 
expression patterns between normal endometrium and endometrial carcinomas 
that profoundly differed in their degree of genomic instability and their 
histopathologic subtype. We detected 121 ploidy-associated proteins to be 
differentially expressed. Interestingly, one protein, TXNL1, was expressed at low 
level in both aneuploid colorectal and endometrial malignancies. In order to 
identify the impact of chromosomal aberrations onto the protein expression in the 
clinical setting, we further mapped genomic imbalances with associated gene and 
protein expression changes of the endometrial cancer patients. AKR7A2 and 
ANXA2 were identified to show similar trends of changes at the gene and protein 
levels. We conclude that the grade of genomic instability correlates with a 
recurrent pattern of chromosomal imbalances and dominates specific gene and 
protein expression changes, irrespective of the histopathological subtypes in 
endometrial cancers. To further elucidate the relevance of highly conserved 
chromosomal aberrations in colorectal cancer, we used specific chromosomal 
aneuploidies in cancer cells and dissected the consequences of genomic imbalances 
on the proteome: three artificial trisomic clones of the diploid colorectal cancer cell 
line DLD1 were analyzed. Chromosomal aneuploidies resulted in a significant 
increase in the average translational activity of proteins encoded by genes not 
located on the trisomic chromosome, indicating pathway-related regulation of the 
cellular proteome equilibrium. A malignancy related protein-profile could also be 
identified for colorectal cancer: 31 proteins showed differential expression between 
normal mucosa and colorectal carcinomas in general, while 39 polypeptides were 
distinctly expressed between diploid and aneuploid carcinomas only. Overall, 
distinct genes and proteins not known to be associated with colorectal and 
endometrial cancer or genomic (in)stability will likely reveal novel targets involved 
in personalized medicine. 
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ABSTRACT 
Aneuploidy is a consistent genetic alteration of the cancer genome. At early steps in the 
sequence of malignant transformation during human tumorigenesis, chromosomal 
aneuploidies can be the first detectable genetic aberrations found. Since late diagnosis 
results in a significant reduction of average survival times, it is of high interest to 
elucidate proteins and pathways of genomic instability or stability. This may also give 
new insight int  tumori nesis and reveal clinically r levant targets for improved 
diagnostics and therapeutics. 
The high variability of protein expression complicates the clinical application of 
‘proteomics’, but continuous improvements i  nstrumen ation, analytical 
methodologies, and labeling chemistries nowadays allow the thorough study and 
detection of tissue protein biomarkers. In addition, the need of strict quality controls of 
samples and clinical validation in large patient cohorts is important to transfer novel 
biomarkers into clinical use. In this manner, we detected genomic instability-specific 
protein alterations in colorectal and endometrial malignancies as detailed in this thesis.  
A comprehensive proteomic analysis f diploid and a euploid colorectal cell lines and 
cli ical tissues was carried out. We fo nd that two prot ins, TXNL1 and HDAC2, were 
not only significantly expressed in our 2-DE analysis and validated by Western 
blotting, but showed expression differences also in clinical samples discerning 
aneuploid from diploid carcinomas. We then analyzed protein expression patterns 
between normal endometrium and endometrial carcinomas that profoundly differed in 
their degree of genomic instability and their histopathologic subtype. We detected 121 
ploidy-associated proteins to be differentially expressed. Interestingly, one protein, 
TXNL1, w s xpressed at low level in both aneuploid colore tal and endometrial 
malignancies. In order to identify the impact of chromosomal aberrations onto the 
protein expression in the clinical setting, we further mapped genomic imbalances with 
associated gene and protein expression changes of the endometrial cancer patients. 
AKR7A2 and ANXA2 were identified to show similar trends of changes at the gene 
and prot in levels. We conclud  that the grade of g nomic instability correlates with a 
recurrent pattern of chromosomal imbalances and dominates specific gene and protein 
expression changes, irrespective of the histopathological subtypes in endometrial 
cancers. To further elucidate the relevance of highly conserved chromosomal 
aberrations in c lorectal canc r, we used specific chromosomal aneuploidies in cancer 
cells and dissect d the cons quen es of g nomic imbalances on the proteome: three 
artificial trisomic clones of the diploid colorectal cancer cell line DLD1 were analyzed. 
Chromosomal aneuploidies resulted in a significant increase in the average translational 
activity of proteins encoded by genes not located on the trisomic chromosome, 
i dic ting pathway-related regulation of the cellular proteome equilibrium. A 
malignancy related protein-profil  could also be identified for colorectal cancer: 31 
proteins showed differential expression between normal mucosa and colorectal 
carcinomas in general, while 39 polypeptides were distinctly expressed between diploid 
and aneuploid carcinomas only. Overall, distinct genes and proteins not known to be 
associated with color ctal and endometrial cancer or gen mic (in)stability will likely 
reveal novel t rg ts involved in personalized medicine. 
